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bjectives The aim of this study was to assess the relative efﬁcacy and safety of the second-gener-
tion TAXUS Liberté paclitaxel-eluting stent (PES) in patients with and without diabetes mellitus.
ackground Diabetic patients suffer from accelerated atherosclerosis and increased risk of resteno-
is after coronary interventions; however, prior data suggest that PES might blunt this effect, provid-
ng equal beneﬁt in diabetic and nondiabetic patients.
ethods A pooled analysis of all 4 TAXUS ATLAS studies was conducted that included 413 diabetic
nd 1,116 nondiabetic subjects treated with the TAXUS Liberté stent for de novo coronary lesions.
ngiographic and intravascular ultrasound outcomes at 9 months and clinical outcomes at 9 and 12
onths were compared in patients with and without diabetes. Propensity score and multivariate
djustments were performed to correct for baseline differences.
esults In-stent angiographic restenosis (13.0% vs. 9.6%, p  0.12), late luminal loss (0.40 mm vs.
.38 mm, p  0.58), and intimal hyperplasia (14.8% vs. 13.4%, p  0.29) were similar for diabetic
nd nondiabetic subjects. After propensity adjustment, 12-month target lesion revascularization
ates were similar for diabetic and nondiabetic subjects (6.4% vs. 4.7%, p  0.18), with no differ-
nces in mortality, myocardial infarction, or stent thrombosis. However, the rate of target vessel re-
ascularization (TVR) was higher for diabetic subjects due to increased TVR outside the target lesion
TVR Remote).
onclusions Similar clinical, angiographic, and intravascular ultrasound outcomes were observed for
oth diabetic and nondiabetic subjects treated with TAXUS Liberté, suggesting that this PES attenuates
he effect of diabetes on restenosis after percutaneous coronary intervention, yielding comparable efﬁ-
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241here is an increased prevalence of atherosclerosis in patients
ith diabetes mellitus (1). Diabetic patients thus tend to have
ore advanced coronary artery disease compared with nondi-
betic patients, with greater plaque burden, and longer lesions
n smaller (or more diffusely diseased) vessels (2–5). Patients
ith diabetes are also more likely to develop restenosis after
reatment with bare metal stents and are at greater risk for
yocardial infarction (MI) and stent thrombosis compared
ith those without diabetes (6–9). The use of drug-eluting
tents, including the TAXUS (Boston Scientific, Natick, Mas-
achusetts) paclitaxel-eluting stent (PES) and the CYPHER
Cordis, Miami, Florida) sirolimus-eluting stent (SES), has
esulted in significantly lower rates of restenosis as compared
ith bare metal stents (10–15). However, the relative efficacy
nd safety of drug-eluting stents in diabetic versus nondiabetic
atients has not been well studied. In this regard, in vitro
tudies have suggested a selective benefit of paclitaxel in
uppressing the neointimal hyperplasia in a diabetic model
16). This study examines whether that observation is sup-
orted clinically from data for diabetic versus nondiabetic
atients treated with the second-generation, thin-strut PES,
AXUS Liberté.
The TAXUS Liberté stent, designed specifically to im-
rove deliverability and conformability and provide more
omogeneous drug distribution, has recently been evaluated
n 4 prospective, controlled studies enrolling patients with
e novo coronary lesions: TAXUS ATLAS (17), TAXUS
TLAS Direct Stent (18), TAXUS ATLAS Long Lesion
19), and TAXUS ATLAS Small Vessel (19). In the
AXUS ATLAS study, the TAXUS Liberté PES was
hown to be similarly effective to the TAXUS Express PES
n reducing restenosis and the need for repeat revascular-
zation in an overall sample containing both diabetic and
ondiabetic patients (17). The current integrated analysis
as undertaken to compare the angiographic, intravascular
ltrasound, and clinical outcomes in medically treated dia-
etic patients treated with the TAXUS Liberté stent in all
TAXUS ATLAS studies with those of the nondiabetic
ohort in the same studies. The objective of this analysis was
o evaluate the effect of the TAXUS Liberté PES on
eointima development and the need for repeat revascular-
zation in patients with and without diabetes.
ethods
evice description. The TAXUS Liberté stent (Boston
cientific Corporation, Natick, Massachusetts) consists
§Auckland City Hospital, Auckland, New Zealand;  Boston Scientific Corpora-
ion, Natick, Massachusetts. This study was supported by Boston Scientific Corpo-
ation, Natick, Massachusetts. The authors wish to disclose the following conflicts of
nterest related to Boston Scientific: research grant support (to Drs. Mahmud, Turco,
opma, Weissman, O’Shaughnessy, and Webster); consulting fees/honoraria (to Drs.
rmiston, O’Shaughnessy, and Cannon); advisory board (to Drs. Ormiston, Turco,
M
1f a balloon-expandable Liberté stent with a biostable
oly(styrene-b-isobutylene-b-styrene) polymer coating
hat contains 1 g/mm2 of paclitaxel in a slow-release formu-
ation. Drug-dosing and release kinetics are virtually identical
o that of the TAXUS Express PES, but the different stent
eometry and thinner strut (0.0038 inch/0.096 mm vs. 0.0052
nch/0.132 mm) design allows for enhanced deliverability and
ore uniform wall coverage.
atient selection, procedure, and follow-up. The study pro-
ocols were approved by local ethics review committees
or included studies, and all patients provided written
nformed consent. Trials are registered on the National
nstitutes of Health website (identifiers NCT00371709,
CT00371423, NCT00371748, and NCT00371475) (20).
Subjects were pooled from the 4 TAXUS ATLAS
tudies. A summary of the individual TAXUS ATLAS
tudy designs is presented in
able 1. Eligibility criteria and
rocedural requirements were
he same in all 4 studies (17–
9). After stent implantation,
ll patients were prescribed
hienopyridine therapy for a
inimum of 6 months. Aspirin
herapy was mandated for at
east 9 months and was recom-
ended indefinitely.
Diabetic subjects were iden-
ified as those treated with at least
hypoglycemic agent (oral or in-
ulin) at the time of enrollment.
y this criterion, the 1,529 sub-
ects enrolled in the 4 TAXUS
TLAS trials were divided into 2
roups: 413 patients with medi-
ally treated diabetes and 1,116
ithout diabetes (Table 1). Clin-
cal follow-up was at 1, 4, 9, and
2 months. Quantitative coronary angiography at 9-month
ollow-up was planned for all patients in the Direct Stent,
ong Lesion, and Small Vessel studies plus 543 randomly
elected patients in TAXUS ATLAS trial. Intravascular ultra-
ound analysis was prespecified for randomly selected patients
n 3 studies—TAXUS ATLAS, Direct Stent, and Long
esion—for a total intravascular ultrasound cohort of 624
atients. Patient follow-up through 12-months is outlined in
igure 1.
opma, O’Shaughnessy, and Cannon); Speakers’ Bureau (to Drs. Turco, Popma,
’Shaughnessy, and Cannon); stock options/equity interest (to Drs. Mandinov and
aim); and salary/full-time employee (to Drs. Mandinov and Baim).
Abbreviations
and Acronyms
%DS  percent diameter
stenosis
CI  confidence interval
HR  hazard ratio
MACE  major adverse
cardiac events
MI  myocardial infarction
MLD  minimum lumen
diameter
PES  paclitaxel-eluting
stent(s)
RVD  reference vessel
diameter
TLR  target lesion
revascularization
TVR  target vessel
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242uantitative coronary angiographic and intravascular ultra-
ound analyses. Quantitative coronary angiographic analy-
es were performed by the same core laboratory (Brigham
nd Women’s Hospital, Boston, Massachusetts) for all
tudies. Standard image acquisition was performed at the
linical sites with 2 or more angiographic projections of the
tenosis, and all procedural and follow-up angiograms were
eviewed with standard morphologic criteria (21,22). With
he contrast-filled injection catheter as the calibration
ource, quantitative coronary angiography was performed
ith a validated automated edge detection algorithm
MEDIS CMS, Version 5.0, Leiden, the Netherlands) (22).
5-mm segment of reference diameter proximal and distal
o the stenosis was used to calculate the average reference
essel diameter (RVD) at baseline, after stent implantation.
inimal lumen diameter (MLD) was measured at these
ame time points within the stent (in-stent analysis), within
he 5-mm proximal and distal edges of the stent and within
he segment between the proximal and distal reference
essel (in-segment analysis). Angiographic percent diameter
tenosis (% DS) was defined as: (1[MLD/RVD])  100.
inary angiographic restenosis was defined as the incidence
f % DS 50% at the qualifying angiographic follow-up.
ate loss was defined as MLD immediately after the
rocedure minus MLD at 9-month follow-up. Restenosis
atterns were qualitatively assessed with the Mehran clas-
ification system (23). Lesion length was defined as the axial
xtent of the lesion that contained a shoulder-to-shoulder
umen reduction by 20%. Angiographic follow-up was
erformed 9 months (14 days) after the index procedure
Table 1. Summary of TAXUS ATLAS Clinical Study Designs
Parameter TAXUS ATLAS
TAXUS ATLA
Direct Sten
Study design Prospective, multicenter, single-
arm, historically-controlled
Prospective, multicente
arm, historically-con
Primary end point 9-month TVR 9-month % diameter st
analysis segment
No. of investigative
sites
61 (North America and
Asia Paciﬁc)
24 (North America and
Asia Paciﬁc)
Lesion criteria De novo, multiple lesions, treatable
with single stent (treatment of
1 nontarget lesion in nontarget
vessel allowed)
De novo, multiple lesio
with single stent (tre
1 nontarget lesion in
vessel allowed)
RVD criteria 2.5–4.0 mm 2.5–4.0 mm
Lesion length 10 and 28 mm 10 and 28 mm
Post-procedure
antiplatelet
therapy
Aspirin: 9 months*; clopidogrel or
ticlopidine: 6 months
Aspirin: 9 months*; clo
ticlopidine: 6 month
Diabetic subjects 220 56
Nondiabetic subjects 651 191
*Aspirin use recommended indefinitely.
RVD reference vessel diameter; TVR target vessel revascularization.nless earlier angiography was required clinically. SVolumetric intravascular ultrasound analyses were per-
ormed by the same core laboratory (Washington Hospital
enter, Washington DC) for all studies. Detailed methods
ave been previously described (24). Images were obtained
mmediately after stent implantation and at 9-month
ollow-up in patients designated for intravascular ultrasound
ollow-up. Images with technically inadequate quality, in-
onsistent pullback speed, and incomplete visualization of
he vascular interface were not analyzed.
The angiographic and intravascular ultrasound Core Lab-
ratories were blinded to all clinical characteristics, includ-
ng the diabetic status.
eﬁnitions. Major adverse cardiac events (MACE) and
tent thromboses were adjudicated by an independent Clin-
cal Events Committee. The clinical and angiographic end
oint definitions were identical for all TAXUS ATLAS
tudies (17,18). Stent thrombosis adjudicated by the Aca-
emic Research Consortium definite/probable definition is
lso reported (25).
tatistical methodology. All end points were analyzed with
he intent-to-treat analysis set. Homogeneity tests were per-
ormed to justify pooling across the 4 TAXUS ATLAS
tudies. The Breslow-Day test was used for binary data and
-way analysis of variance was employed for continuous vari-
bles. Values of p  0.05 (the lowest p value was 0.31)
uggested that the treatment effect between the diabetic and
ondiabetic patients across studies is homogeneous and that all
TAXUS ATLAS studies can be pooled together.
Baseline, post-procedure, and follow-up data are summa-
ized with descriptive statistics, with data presented as
roportions (%, count/sample size) or mean  SD. The
TAXUS ATLAS
Small Vessel
TAXUS ATLAS
Long Lesion
le- Prospective, multicenter, single-
arm, historically-controlled
Prospective, multicenter, single-
arm, historically-controlled
, 9-month % diameter stenosis,
analysis segment
9-month % diameter stenosis,
analysis segment
23 (North America and
Asia Paciﬁc)
24 (North America and
Asia Paciﬁc)
atable
t of
arget
De novo, multiple lesions, treatable
with single stent (treatment of
1 nontarget lesion in nontarget
vessel allowed)
De novo, multiple lesions, treatable
with single stent (treatment of
1 nontarget lesion in nontarget
vessel allowed)
2.2–2.5 mm 2.7–4.0 mm
10 and 28 mm 26 and 34 mm
el or Aspirin: 9 months*; clopidogrel or
ticlopidine: 6 months
Aspirin: 9 months*; clopidogrel or
ticlopidine: 6 months
95 42
166 108S
t
r, sing
trolled
enosis
ns, tre
atmen
nont
pidogr
student t test was used for comparing continuous variables.
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243he chi-square test or Fisher exact test, as appropriate, was
sed for comparing 2 proportions. Kaplan-Meier product-
imit method and log-rank test were used to assess time-to-
vent end points between the 2 groups.
Due to significant differences in baseline characteristics
etween diabetic and nondiabetic patients, clinical, angio-
raphic, and intravascular ultrasound outcomes were adjusted
ith propensity score analysis. In addition, 1-year clinical
utcomes were also adjusted with multivariate modeling, to
onfirm the results of the propensity analysis.
Propensity score analysis (26–29) is used to balance 2
onrandomized groups on the basis of observed covariates in
rder to equalize the baseline differences associated with a
reatment or disease state and give a more accurate estimate of
he effect of the treatment or the disease (30). Use of this
ropensity score allows for adjustment of baseline differences
other than the presence of diabetes) between the diabetic and
ondiabetic groups. Propensity score analysis was performed
ith a hierarchical logistic regression model with a stepwise
election process and an entry/exit criterion of 0.10. The
ogistic regression model creates a score on the basis of the
Figure 1. Patient Flow Through 9- and 12-Month Follow-Up
Patient ﬂow of all diabetic and nondiabetic subjects enrolled in the TAXUS AT
quantitative coronary angiography; IVUS  intravascular ultrasound.ropensity that a patient belongs to 1 of the 2 groups being (ompared. The propensity score for the likelihood of belonging
o the diabetic group ordered patients of the 2 analysis sets into
uintiles. Each quintile contained patients with similar scores
nd more balanced baseline characteristics, thus allowing for
ore like-to-like comparisons between the 2 groups and
djustment of the outcomes. All demographic data and lesion
haracteristics listed in Table 2 and the following procedural
haracteristics were considered for adjustment: pre-procedure
hrombolysis in Myocardial Infarction flow; nontarget lesion
reated; maximum balloon/artery ratio; maximum overall pres-
ure; glycoprotein IIb/IIIa inhibitor use during index proce-
ure; and pre-procedure aspirin and thienopyridine use.
Multivariate adjustment was also performed for 1-year
linical outcomes, with the same variables that were
onsidered for propensity score adjustment. In addition,
vent-free survival estimates/diabetic status were pro-
uced by stratification of multivariate Cox regression
odels in a 2-stage multivariate analysis.
Multivariate analyses were used to determine predictors
f 12-month mortality, MI, target vessel revascularization
TVR), TVR Remote, and target lesion revascularization
irect Stent, Long Lesion, and Small Vessel Studies. mo  month; QCA LAS, DTLR) in all subjects. All characteristics listed in the
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244receding text along with diabetes were considered. A
-stage multivariate analysis was conducted for each out-
ome with the Cox regression model. In the first stage, the
redictors were determined by stepwise selection with an
ntry and exit criterion for each candidate of p  0.05. In
he second stage, a multivariate model was created only
onsidering the variables found to be significant predictors
n the first stage for each outcome.
Differences were considered to be statistically significant
hen the p value was 0.05.
esults
aseline characteristics and procedural outcomes. Baseline
emographic data and angiographic lesion characteristics
re shown in Table 2. Subjects with medically treated
iabetes were more likely to be women and to have a
Table 2. Baseline Demographic Data
Male, n (%)
Age (yrs)
Cardiac history, n (%)
Percutaneous coronary intervention
Coronary artery bypass graft
Previous MI
Congestive heart failure
Stable angina
Unstable angina
Silent ischemia
Risk factors and comorbidities, n (%)
Current smoking
Hyperlipidemia requiring medication
Hypertension requiring medication
Renal disease
Baseline lesion characteristics by quantitative coronary angiography
Target vessel LAD (%)
RVD (mm)
MLD (mm)
% diameter stenosis
Lesion length (mm)
Eccentric lesions (%)
Bend 45° (%)
Calciﬁcation (%)
Tortuosity (%)
Branch vessel disease (%)
Total occlusion (%)
Thrombus (%)
Ulceration (%)
Modiﬁed ACC/AHA type B2 or C lesion (%)
Numbers shown are mean SD (n) or % (n/N).
ACCAmerican College of Cardiology; AHAAmericanHeart Association; LAD left anterior de
Vessel Diameter.istory of previous revascularization (both percutaneous coronary intervention and coronary artery bypass graft
urgery), congestive heart failure, hyperlipidemia, hyper-
ension, and chronic renal insufficiency but were less
ikely to be smokers. Diabetic subjects had smaller
ngiographic reference diameter and smaller final im-
lanted stent size. All other baseline clinical and angio-
raphic lesion characteristics were matched between the 2
roups (Table 2). Procedural characteristics and anti-
latelet use are shown in Table 3. Use of dual antiplatelet
herapy was similar between diabetic and nondiabetic
atients pre-procedure, at discharge, and at 9-month
ollow-up. However, diabetic patients had significantly
igher dual antiplatelet therapy use at 1 year compared
ith nondiabetic patients.
ngiographic end points at 9 months. There were no sig-
ificant differences in 9-month in-stent angiographic out-
Nondiabetic
(n  1,116)
Diabetic
(n  413) p Value
94 (71.1) 242 (58.6) 0.001
2 10.9 62.4 10.3 0.74
36 (30.1) 157 (38.0) 0.003
71 (6.4) 39 (9.4) 0.04
25 (29.1) 122 (29.5) 0.87
39 (3.5) 37 (9.0) 0.001
87 (61.6) 239 (57.9) 0.19
47 (31.1) 132 (32.0) 0.75
81 (7.3) 42 (10.2) 0.06
69 (24.1) 78 (18.9) 0.03
35 (74.8) 358 (86.7) 0.001
45 (66.8) 358 (86.7) 0.001
38 (3.4) 27 (6.5) 0.007
2.8 (478/1,116) 39.7 (163/411) 0.27
7 0.53 (1,116) 2.55 0.56 (411) 0.001
4 0.34 (1,116) 0.81 0.35 (411) 0.10
4 11.54 (1,116) 68.29 11.35 (411) 0.94
7 7.8 (1,116) 16.4 7.7 (410) 0.14
9.0 (547/1,116) 44.0 (181/411) 0.08
9.5 (329/1,116) 28.0 (115/411) 0.57
0.7 (343/1,116) 28.8 (118/410) 0.46
4.2 (159/1,116) 13.1 (54/411) 0.58
1.3 (125/1,107) 11.9 (49/411) 0.73
0.8 (9/1,115) 1.0 (4/411) 0.76
3.8 (42/1,116) 3.2 (13/411) 0.58
6.1 (68/1,116) 5.1 (21/411) 0.47
6.3 (851/1,116) 76.2 (313/411) 0.97
g coronary artery;MLDminimum lumendiameter;MImyocardial infarction; RVD Reference7
62.
3
3
6
3
2
8
7
4
2.6
0.8
68.3
15.
4
2
3
1
1
7
scendinomes, regardless of propensity-adjustment. Late loss was
s
i
a
n
B
a
t
i
w
h
d
g
t
s
a
I
w
p
e
t
o
g
s
a
I
4
c
(
T
l
i
l
U
C
1
s
c
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 3 , 2 0 0 9
M A R C H 2 0 0 9 : 2 4 0 – 5 2
Mahmud et al.
TAXUS Liberté Stent in Patients With Diabetes
245imilar for diabetic and nondiabetic subjects and nearly
dentical after propensity score adjustment (Table 4). In
ddition, the distribution curves of late loss for diabetic and
ondiabetic subjects were virtually superimposable (Fig. 2).
inary in-stent restenosis rate and in-stent % DS, whether
djusted or unadjusted, were not statistically different be-
ween diabetic and nondiabetic patients. The pattern of
n-stent restenosis was also similar between the 2 groups
ith 2% of the study sample presenting with proliferative
yperplasia or total occlusion at follow-up regardless of
iabetic status (Fig. 3).
In-segment late loss was similar for the 2 patient
roups regardless of adjustment. There was a trend
oward higher rates of in-segment binary restenosis in
ubjects with diabetes; however, after propensity score
djustment the rates were similar for the 2 groups.
n-segment % DS was significantly increased in patients
ith diabetes; this difference became nonsignificant after
ropensity score adjustment. Edge analysis was used to
Table 3. Procedural Characteristics and Use of Antip
Nondia
(n  1,
Procedural characteristics
Procedure time (min) 49.0 25.
Pre-dilation (%) 83.1 (927
Maximum pressure (atm) 15.7 3.3
Maximum stent size (mm) 3.1 0.6
Post-dilation (%) 50.8 (567
Use of dual antiplatelet therapy*
Pre-procedure 99.1 (1,10
Discharge 99.6 (1,10
9 months 61.7 (673
1 yr 52.2 (565
Numbers shown are mean SD (n) or % (n/N).
*Aspirin and thienopyridine (clopidogrel or ticlopidine).
Table 4. Angiographic and Intravascular Ultrasound Results at 9 Months
Unadjusted Values
Nondiabetic
(n  1,116)
Diabetic
(n  413)
In-stent measures
Late loss* 0.38 0.50 (724) 0.40 0.53 (276
% diameter stenosis* 20.63 19.51 (726) 23.25 21.47 (27
Restenosis (%)* 9.6 (70/726) 13.0 (36/276)
% intimal hyperplasia† 13.4 10.7 (321) 14.8 12.4 (91)
% intima-free length† 33.0 32.7 (321) 27.1 28.1 (92)
In-segment measures
Late loss* 0.24 0.46 (727) 0.26 0.49 (278
% diameter stenosis* 28.47 17.22 (729) 32.12 18.98 (27
Restenosis (%)* 12.6 (92/729) 16.9 (47/278)Numbers shown are mean SD (n) or % (n/N). *Quantitative coronary angiography. †Intravascular ultrasovaluate the difference in the in-segment % DS between
he 2 groups. Although there were no differences in % DS
r restenosis rates at the proximal edge between the 2
roups, both % DS and restenosis at the distal edge were
ignificantly increased in diabetic compared with nondi-
betic subjects (Fig. 4).
ntravascular ultrasound end points at 9 months. A total of
27 patients (68% of the intravascular ultrasound cohort)
ompleted 9-month intravascular ultrasound follow-up
Fig. 1), and 413 of these patients had analyzable films. The
AXUS Liberté stent suppressed neointima growth simi-
arly in diabetic and nondiabetic subjects with similar %
ntimal hyperplasia in both groups (Table 4). Intima-free
ength of the stent was also similar for the 2 groups.
nadjusted and adjusted results were concordant.
linical efﬁcacy of TAXUS Liberté in diabetic subjects at 9 and
2 months. Clinical follow-up at 9 and 12 months demon-
trated a higher rate of overall TVR for diabetic subjects as
ompared with nondiabetic subjects, a difference that re-
t Therapy
Diabetic
(n  413) p Value
2) 46.9 25.8 (411) 0.16
) 85.7 (354/413) 0.21
) 15.9 3.2 (413) 0.36
) 2.9 0.6 (413) 0.001
45.5 (188/413) 0.07
) 99.5 (411/413) 0.53
) 100.0 (413/413) 0.58
63.0 (250/397) 0.67
57.9 (231/399) 0.0499
Propensity Score-Adjusted Values
p Value
Nondiabetic
(n  1,116)
Diabetic
(n  413) p Value
0.58 0.37 0.38 0.80
0.07 20.5 21.5 0.49
0.12 9.7 9.6 0.99
0.29 13.8 14.6 0.59
0.12 34.3 27.0 0.08
0.46 0.22 0.25 0.54
0.004 28.5 30.2 0.20
0.08 12.9 12.5 0.85latele
betic
116)
7 (1,11
/1,116
(1,115
(1,116
/1,116)
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246ained statistically significant after propensity adjustment
Table 5). The 9- and 12-month rates of both TLR and
emote TVR were also significantly higher for diabetic
ubjects versus nondiabetic subjects. However, after propen-
ity adjustment (Table 5), the TLR rates were similar
etween the 2 cohorts with a trend toward a higher rate of
emote TVR (in the target vessel but outside the target
esion) in the diabetic cohort. The results at 12-month
ollow-up were corroborated by multivariate adjustment
Fig. 5) demonstrating that the diabetic subjects had signif-
cantly increased risk of TVR, driven by a higher risk of
VR Remote (non-TLR TVR); however, the risk of TLR
as comparable for the 2 groups.
afety of TAXUS Liberté in diabetic subjects at 12 months.
ubjects with diabetes had comparable rates of all-cause
ortality, cardiac death, and MI at 9 and 12 months
ompared with nondiabetic subjects (Table 5). The rates of
tent thrombosis by protocol and Academic Research Con-
ortium definition were also similar between the 2 groups
Table 5). Unadjusted/protocol stent thrombosis rates at 12
Figure 2. Cumulative Frequency Distribution of 9-Month In-Stent and
In-Segment Late Loss by Quantitative Coronary Angiography
Subjects with and without diabetes treated with the TAXUS Liberté Stent in
the TAXUS ATLAS studies. (A) In-stent; and (B) in-segment. Intent-to-treat,
angiographic subset (n  1,201; diabetic: 334; nondiabetic: 867).onths were concordant with those after multivariate (haz- frd ratio [HR]: 1.37; 95% confidence interval [CI]: 0.34 to
.5; p  0.66) and propensity score adjustment (Table 5).
ultivariate predictors of clinical outcomes at 12 months.
ultivariate analysis was performed for numerous clinical
nd procedural variables to determine the risk factors for
verall mortality, cardiac mortality, MI, TVR, TLR, and
emote TVR (Table 6). Diabetes was not found to be a risk
actor for death, MI, or TLR 12 months after TAXUS
iberté stent implantation. However, the presence of dia-
etes remained a predictor of repeat TVR (HR: 1.77; 95%
I: 1.24 to 2.52; p  0.002) and remote (nontarget lesion)
VR (HR: 1.71; 95% CI: 1.03 to 2.82; p  0.04) at 12
onths.
iscussion
his study has a number of important findings that pertain
o medically treated diabetic patients treated with the
econd-generation TAXUS Liberté PES. First, angio-
raphic and intravascular ultrasound analyses both demon-
trate that this stent reduces neointimal proliferation in
iabetic subjects to a level that is comparable to that seen in
ondiabetic subjects. Second, when restenosis develops, its
attern is dominated by focal restenosis in both diabetic and
ondiabetic subjects. Third, these angiographic and intra-
ascular ultrasound findings are accompanied by rates of
linical restenosis of the target lesion (TLR) that are similar
or diabetic and nondiabetic subjects. Fourth, the increased
ates of overall TVR and MACE seen in diabetic subjects
re driven predominantly by TVR Remote (i.e., TVR
utside the stented lesion) rather than events driven within
he stented segment. Fifth, at 12-month follow-up, no
ncrease in the likelihood of stent thrombosis, MI, or death
xists with this stent in diabetic subjects.
The active ingredient in the TAXUS Liberté stent,
aclitaxel, effectively blocks smooth muscle cell proliferation
nd migration through multiple mechanisms, including
tabilization of microtubules to cause G1 arrest (31–33) and
nhibition of the Ras/mitogen-activated protein kinase
athway (16,34). When these pathways are affected, the
lternative pro-survival mechanism for the smooth muscle
ell is through modulation of the AKT-dependent mTOR
35–37) and/or FoxO3a signaling pathways. The ability to
ot promote activation of AKT under the hyperglycemic
tate typically seen in the diabetic metabolic state (16), and
o strongly inhibit insulin-dependent AKT phosphorylation
35,36), allows paclitaxel to maintain its inhibition of
estenosis in diabetic models.
The current study supports the translation of these in vitro
ndings to the clinical realm by showing that paclitaxel can
rovide a similarly low degree of neointimal proliferation in
iabetic subjects and nondiabetic subjects. Indeed, the angio-
raphic in-stent parameters of late luminal loss and % DS were
ound to be very similar in diabetic and nondiabetic patients
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247reated with this second-generation PES. Despite slightly
maller reference vessels at baseline in the diabetic patients,
heir in-stent binary restenosis rates were comparable to those
f nondiabetic subjects and the pattern of restenosis at the time
f repeat revascularization for both groups was predominantly
ocal in nature, a pattern easier to treat than proliferative or
iffuse restenosis (23). Angiographic findings were corrobo-
ated by intravascular ultrasound results, which demonstrated
hat the in-stent intimal hyperplasia was similar between
iabetic and nondiabetic subjects, further supporting that this
ES can inhibit neointimal growth even in the diabetic state.
Figure 3. ISR Patterns in Diabetic and Nondiabetic Patients
The frequency of individual patterns of in-stent restenosis (ISR) in subjects
with and without diabetes treated with the TAXUS Liberté Stent in TAXUS
ATLAS studies. Intent-to-treat, angiographic subset (n  1,201; diabetic:
334; nondiabetic: 867).
Figure 4. Angiographic Edge Analysis
Frequency of percent diameter stenosis (A) and binary restenosis (B) 5 mm pr
tus treated with the TAXUS Liberté Stent in TAXUS ATLAS studies. Intent-to-treat, anhis is consistent with a recent meta-analysis of the TAXUS
V, V de novo, and VI trials that also shows comparable
uppression of neointimal hyperplasia by quantitative intravas-
ular ultrasound analysis in diabetic subjects and nondiabetic
ubjects with the first generation PES TAXUS Express (38).
Whereas there were no significant differences between
iabetic and nondiabetic patients in any in-stent measures, %
S in the analysis segment was significantly increased in
atients with diabetes, driven by a greater % DS at the distal
dge. The increased rate of distal edge restenosis in diabetic
atients as compared with nondiabetic subjects might be
aused by more pronounced restenotic response within the
njured vessel segments that remained uncovered by the PES
r more rapid disease progression outside the stent in patients
ith diabetes. However, in-segment % DS was not signifi-
antly different between groups after propensity score adjust-
ent. Similarly, the unadjusted TLR rates were higher in the
iabetic cohort, which presented with smaller diameter vessels,
lightly longer lesions, increased comorbidities, and more edge
estenosis than the nondiabetic cohort. Importantly, no signif-
cant difference in the likelihood of TLR remained after
ropensity score or multivariate adjustment correcting for
aseline differences between the 2 groups. These findings
orroborate the results from a meta-analysis of 5 TAXUS
xpress randomized studies that demonstrated TLR reduction
or the first-generation PES compared with bare metal stents
n cohorts with diabetes (HR: 0.42; 95% CI: 0.30 to 0.60) and
ithout diabetes (HR: 0.47; 95% CI: 0.38 to 0.59) (15).
The higher MACE rate seen in the diabetic cohort was
ccounted for by the increased TVR Remote (non-TLR) in
iabetic subjects. Because diabetes is a systemic disease, pro-
l and distal to each stent edge in subjects with and without diabetes melli-oxima
giographic subset (n  1,201; diabetic: 334; nondiabetic: 867).
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248ression of atherosclerosis or formation of new lesions remote
rom the index treated lesion is expected, as is the inability of
ocal treatment by a drug-eluting stent to reduce progressive
isease beyond the treated vessel segment. In patients treated
ith the paclitaxel-eluting TAXUS Liberté stent, diabetes thus
emained a significant risk factor for repeat TVR at 1 year due
o revascularization outside the target lesion.
In a meta-analysis of 5 TAXUS Express randomized
tudies with a follow-up 4 years after stenting, diabetic
atients treated with the TAXUS Express stent com-
ared with those receiving bare metal stents demon-
trated similar rates of all-cause mortality (8.4% TAXUS
s. 10.3% bare metal stent, p  0.61), Q-wave MI (0.5%
AXUS vs. 1.5% bare metal stent, p  0.26), and
cademic Research Consortium definite/probable stent
hrombosis (2.2% TAXUS vs. 1.4% bare metal stent, p 
.74) and thus demonstrated a similar safety profile (15).
he present study demonstrates that patients with and
Table 5. Clinical Outcomes at 9 and 12 Months
Unadjusted Values
Nondiabetic
(n  1,116)
Diabetic
(n  413)
9 months, % (n/N)
MACE 9.7 (107/1,108) 14.0 (57/407)
Cardiac death or MI 4.2 (46/1,108) 3.4 (14/407)
Cardiac death 0.8 (9/1,108) 0.5 (2/407)
MI 3.4 (38/1,108) 3.4 (14/407)
Q-wave MI 0.6 (7/1,108) 0.5 (2/407)
Non–Q-wave MI 2.8 (31/1,108) 2.9 (12/407)
TVR overall* 6.5 (72/1,108) 11.8 (48/407)
TLR 4.5 (50/1,108) 7.4 (30/407)
TVR-remote 3.1 (34/1,108) 5.7 (23/407)
All death 1.1 (12/1,108) 1.0 (4/408)
Stent thrombosis
Per protocol 0.5 (6/1,102) 0.5 (2/404)
Deﬁnite/probable† 0.7 (8/1,102) 0.5 (2/404)
12 months, % (n/N)
MACE at 1 yr 10.7 (117/1,096) 15.9 (64/403)
Cardiac death or MI 4.3 (47/1,096) 4.0 (16/403)
Cardiac death 0.8 (9/1,096) 0.7 (3/403)
MI 3.6 (39/1,096) 3.7 (15/403)
Q-wave MI 0.6 (7/1,096) 0.5 (2/403)
Non–Q-wave MI 2.9 (32/1,096) 3.2 (13/403)
TVR overall* 7.4 (81/1,096) 13.2 (53/403)
TLR 4.9 (54/1,096) 8.2 (33/403)
TVR-remote 3.7 (41/1,096) 6.5 (26/403)
All death 1.3 (14/1,097) 1.7 (7/406)
Stent thrombosis 0.6 (6/1,087) 0.8 (3/399)
Data presented as proportions (%, count/sample size). *Patients with both a target lesion revascula
analysis of overall TVR. †Academic Research Consortium definition (25).
MACEmajor adverse cardiac events; MImyocardial infarction.ithout diabetes had similar rates of death, MI, and stent ihrombosis at 1 year after TAXUS Liberté PES implan-
ation. This suggests a similar safety profile for the
AXUS Liberté stent in diabetic and nondiabetic pa-
ients. Although diabetes has been recognized as a
ardiovascular risk factor (30) and higher rates of death
nd MI can be anticipated in diabetic patients with
onger follow-up beyond 1 year, the current analysis did
ot identify any incremental risk of using PES in patients
ith diabetes at 1 year.
tudy limitations. The TAXUS ATLAS, Direct Stent,
ong Lesion, and Small Vessel studies are prospective
tudies evaluating the TAXUS Liberté stent in patients with
trict inclusion/exclusion criteria; because patients enrolled
n these trials were carefully selected, the results might only
pply to the types of patients and lesions included in these
studies. Assessment of diabetic status in these subjects was
lso not ideal, because plasma glucose, hemoglobin A1c,
nd glucose-tolerance data were not obtained. Biological
Propensity Score Adjusted Values
p value
Nondiabetic
(n  1,116)
Diabetic
(n  413) p value
0.02 9.9 12.6 0.16
0.53 4.1 3.5 0.63
0.74 0.7 0.4 0.29
0.99 3.4 3.5 0.96
0.99 0.6 0.6 0.99
0.88 2.9 2.9 0.95
0.001 6.7 10.1 0.04
0.03 4.6 6.1 0.26
0.02 3.2 5.1 0.10
0.99 1.0 0.9 0.83
0.99 0.5 0.6 0.90
0.99 0.7 0.6 0.82
0.006 10.9 14.1 0.12
0.79 4.3 4.1 0.87
0.99 0.7 0.7 0.88
0.88 3.6 3.7 0.90
0.99 0.6 0.6 0.98
0.76 3.0 3.2 0.89
0.001 7.6 11.0 0.04
0.02 4.7 6.4 0.18
0.02 3.4 5.6 0.08
0.51 1.2 1.6 0.59
0.71 0.5 0.8 0.58
(TLR) and a target vessel revascularization (TVR)-remote are only counted once in the per-patientrizationndicators of diabetic status might have detected more
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249Figure 5. 12-Month Freedom From Adverse Outcomes
Unadjusted (A, C, E, G) and multivariate-adjusted (B, D, F, H) freedom from all-cause mortality (A, B), target vessel revascularization (TVR) (C, D), TVR Remote
(non-target lesion revascularization [TLR] TVR) (E, F), and TLR (G, H). Diabetic (n  413) and nondiabetic (n  1,116) intent-to-treat subjects treated with the
TAXUS Liberté Stent in TAXUS ATLAS studies. Event-free survival  1.5 SEM. CI  conﬁdence interval.
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250atients with early-stage diabetes than the currently used
efinition of “treatment with oral hypoglycemic agents or
nsulin.” In addition, because the analysis of diabetic pa-
ients was restricted to those receiving medical treatment,
he results might not be extrapolative to patients with
re-diabetes or hypoglycemia managed by change in life-
tyle or diet. Furthermore, within these constraints, the
omparison of the diabetic versus nondiabetic cohort was a
ost-hoc analysis and might be underpowered to detect
ifferences in low-frequency safety events such as stent
hrombosis, death, or MI. In this study, significant differ-
nces in baseline characteristics also existed between the 2
ohorts that might be related to diabetes. However, several
f these variables are also independent predictors of adverse
vents after coronary interventions, and metabolic features
f the diabetic state confer additional risks that are unique
o the diabetic condition. Therefore, propensity score and
ultivariate adjustment were used to partially compensate
or baseline differences. Although this might be suboptimal,
Table 6. Multivariate Predictors of Clinical Outcomes
Significant Predictors Coefficient
All-cause mortality
Age at procedure 0.10
Smoking, current 1.11
Post-procedure TIMI ﬂow 1.61
Pre-procedure MLD* 1.45
Cardiac mortality
Age at procedure 0.11
Post-procedure TIMI ﬂow 2.16
MI
Age at procedure 0.03
Glycoprotein IIb/IIIa inhibitor
during procedure
0.73
Nonstudy stents implanted 1.44
Unstable angina 0.54
Post-procedure TIMI ﬂow 1.95
TVR
Medically treated diabetes 0.57
Pre-procedure RVD* 0.72
Medication for hyperlipidemia 0.43
TLR
Total length implanted 0.03
Pre-procedure RVD* 0.67
Calciﬁcation* 0.59
TVR-Remote
Medically treated diabetes 0.53
Pre-procedure RVD* 0.94
Medication for hyperlipidemia 0.66
Note that negative () coefficients with hazard ratios 1.0 indicate
quantitative coronary angiography.
CI confidence interval;MImyocardial infarction;MLDminimu
lesion revascularization; TVR target vessel revascularization; RVDt provides a method to adjust for baseline imbalance when eandomization is not possible. It is important to note that
he intent of reporting propensity- and multivariate-
djusted results is not to suggest “new” rates but rather to
nsure more like-to-like comparisons between the 2 patient
roups so that a less biased assessment of paclitaxel’s ability
o inhibit in-stent restenosis in the diabetic metabolic state
an be ascertained.
onclusions
he TAXUS Liberté is a second-generation paclitaxel-
luting stent with reduced stent strut thickness and a better
elivery system compared with the first-generation PES.
hen used for treatment of single simple and complex de
ovo native coronary lesions, this stent is associated with
early identical late luminal loss, restenosis, and neointimal
yperplasia in both diabetic and nondiabetic subjects. This
as accompanied by similar and low rates of adjusted TLR
t 12-month follow-up in both groups and provides clinical
Year
SE
Hazard Ratio
(95% CI) p Value
0.03 1.11 (1.06–1.17) 0.001
0.52 3.04 (1.11–8.35) 0.03
0.60 0.20 (0.06–0.64) 0.007
0.74 0.23 (0.06–1.00) 0.0499
0.03 1.12 (1.05–1.19) 0.001
0.57 0.12 (0.04–0.36) 0.001
0.01 1.04 (1.01–1.06) 0.01
0.29 2.08 (1.18–3.69) 0.01
0.73 4.23 (1.02–17.61) 0.047
0.28 1.71 (0.99–2.96) 0.06
0.35 0.14 (0.07–0.28) 0.001
0.18 1.77 (1.24–2.52) 0.002
0.17 0.49 (0.35–0.68) 0.001
0.20 0.65 (0.44–0.96) 0.03
0.01 1.03 (1.01–1.05) 0.002
0.22 0.51 (0.33–0.78) 0.002
0.28 0.55 (0.32–0.95) 0.03
0.26 1.71 (1.03–2.82) 0.04
0.25 0.39 (0.24–0.64) 0.001
0.27 0.52 (0.30–0.87) 0.01
es that are inversely associated with the event. *As determined by
ndiameter; TIMIThrombolysis InMyocardial Infarction; TLR target
ce vessel diameter.at 1
variabl
m lumevidence that the paclitaxel-eluting TAXUS Liberté stent
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251lunts any deleterious effect of diabetes on the development
f restenosis within the stented segment. The increased
eed for repeat intervention in diabetic subjects as compared
ith nondiabetic subjects, however, is due to higher rates of
emote TVR likely due to accelerated atherosclerosis in
iabetic subjects. The safety profile of the TAXUS Liberté
tent is comparable for diabetic and nondiabetic subjects as
vident by similar rates of death, MI, and stent thrombosis
n the 2 patient subsets. Therefore, the TAXUS Liberté
ES is an effective treatment option for de novo coronary
esions in patients with diabetes but has no effect on the
evelopment and progression of atherosclerosis beyond the
reated lesion.
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